Bellerophon Therapeutics announced clearance of its Investigational New Drug, IND, application from the Center for Drug Evaluation of China’s National Medical Products Administration, NMPA, to conduct a Phase 3 clinical trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease, fILD, in China. The study will utilize Moderate to Vigorous Physical Activity, MVPA, as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. "We are delighted to expand our clinical program with the aim of bringing INOpulse to patients in need in Greater China," said Peter Fernandes, Bellerophon’s Chief Executive Officer. "INOpulse has the potential to become the first therapy to treat an fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. This IND clearance further underscores the potential of INOpulse to improve activities of daily living and quality of life in patients with fILD, and supports the use of our novel primary endpoint, MVPA, which we are also utilizing in our ongoing Phase 3 REBUILD study in the U.S."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLPH:
- Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease
- Bellerophon: Last patient enrolled in INOpulse study for treatment of fILD
- Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
- Biotech Alert: Searches spiking for these stocks today
- Bellerophon Therapeutics Soars After Licensing Agreement